Aim To investigate the impact of pain intensity of postherpetic neuralgia (PHN) patients. Methods This cross sectional study included 30 PHN patients attended to the Dermatology and Venereology Department of the School of Medicine of Universitas Sumatera Utara during the period between April 2019 and October 2019. Zoster Brief Pain Inventory questionnaire including the worst pain in 24 hours and the level of interference with seven domains of quality of life (QoL) (general activity, mood, walking ability, working, relationship with other people, sleep and enjoyment of life) were used. Pearson's correlation (r) was categorized as very weak (0.0-< 0.2), weak (0.2-< 0.4), moderate (0.4-< 0.6), strong (0.6-<0.8), and very strong (0.8-1.0). Results There was a very strong correlation between worst pain intensity and mood disturbance (r=0.846) and working status (r=0.818). Worst pain intensity had a strong correlation with general activity (r=0.673), relationship with other people (r=0.653), sleep (r=0.774) and disturbance of enjoyment of life (r=0.783). Therefore, the correlation between worst pain intensity and walking ability was moderate (r=0.475). The worst pain intensity had a significant correlation with all seven domains of QoL (p< 0.05). Conclusion Pain intensity influences the QoL with directly proportional correlation between pain intensity and disturbance of QoL.
Schmader K, Dworkin R;, Watson C, Gershon A, Oxman M. The epidemiology and natural history of herpes zoster and post herpetic neuralgia. Springer; 2017.
2.
Pusponegoro E, Nilasari H, Lumintang H, Niode N, Daili S, Djauzi S. Buku Panduan Herpes Zoster di Indonesia (Indonesia Shingles Book Guide). BP FKUI. 2014.
3.
Schmader K, Oxman M, Varicella H, Zoster ;, Goldsmith L, Katz S, et al. Fitzpatrick’s Dermatology in General Medicine. The Mc Graw Hill Company Inc; 2012. p. 2393–8.
4.
Chen Q, Hsu T, Chan R, Kawai K, Acosta C, Walia A, et al. Clinical and economic burden of herpes zoster and postherpetic neuralgia in patients from the national skin center. Dermatol Sin. 2015. p. 201–5.
5.
Lukas K, Edte A, Bertrand I. The impact of herpes zoster and post herpetic neuralgia on quality of life: patient-reported outcomes in six European countries. Z Gesundh Wiss. 2012. p. 441–51.
6.
Serpell M, Gater A, Carrol S, Abetz-Webb L, Mannan A, Johnson R. Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study. Health Qual Life Outcomes. 2014. p. 92.
7.
Coplan P, Schmader K, Nikas A, Chan I, Choo P, Levin M, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J Pain. 2004. p. 344–56.
8.
Dahlan M. Statistik untuk kedokteran dan kesehatan (Statistic for Medicine and Health). Salemba Medika; 2014.
9.
Van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing. 2006. p. 132–7.
10.
Muñoz-Quiles C, López-Lacort M, Orrico-Sánchez A, Díez-Domingo J. Impact of postherpetic neuralgia: A six year population-based analysis on people aged 50 years or older. J Infect. 2018. p. 131–6.
11.
Weaver B. The burden of herpes zoster and postherpetic neuralgia in the United States. J Am Osteopath Assoc. 2007. p. 2–7.
12.
Belfer I. Pain in women. Agri Pain. 2017. p. 51–4.
13.
Schmidt-Ott R, Schutter U, Simon J, Nautrup B, Krempelhuber V, Gopala A, et al. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥ 50 years: a prospective study. J Infect. 2018. p. 475–82.
14.
Nahm F, Kim S, Kim H, Shin J, Yoo S, Yoon M, et al. Survey on the treatment of postherpetic neuralgia in Korea; multicenter study of 1.414 Patients. Korean J Pain. 2013. p. 21–6.
15.
Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin ther. 2013. p. 612–22.
16.
Nakamura H, Mizukami A, Adachi K, Matthews S, Holl K, Asano K, et al. Economic burden of herpes zoster and postherpetic neuralgia in adults 60 years of age or older: results from a prospective, physician practice-based cohort study in Kushiro. Japan. Drugs Real World Outcomes. 2017. p. 187–98.
17.
Johnson R, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2014. p. 1581–95.
18.
Atkinson T, Mendoza T, Sit L, Passik S, Scher H, Cleeland C, et al. The brief pain inventory and its “pain at its worst in the last 24 hours” item: clinical trial endpoint considerations. Pain Med. 2010. p. 337–46.
19.
FDA Draft Guidance for Industry. Analgesic Indications: Developing Drugs and Biological Products. U.S. Food and Drug Administration; 5AD.
20.
Wyrwich K, Kawata A, Thompson C, Holmstrom S, Stoker M, Wiklund I. Validation of the self-assessment of treatment questionnaire among patients with postherpetic neuralgia. Pain Res Treat. 2012. p. 621619.
21.
Schlereth T, Heiland A, Breimhorst M, Féchir M, Kern U, Magerl W, et al. Association between pain, central sensitization and anxiety in postherpetic neuralgia. Eur J Pain. 2014. p. 193–201.
22.
Saxena A, Lakshman K, Sharma T, Gupta N, Banerjee B, Singal A. Modulation of serum BDNF levels in postherpetic neuralgia following pulsed radiofrequency of intercostal nerve and pregabalin. Pain Manag. 2016. p. 217–27.
23.
Chen M, Wei H, Su T, Li C, Lin W, Chang W, et al. Risk of depressive disorder among patients with herpes zoster: a nationwide population-based prospective study. Psychosom Med. 2014. p. 285–91.
24.
Aunhachoke K, Bussaratid V, Chirachanakul P, Chua-Intra B, Dhitavat J, Jaisathaporn K, et al. Measuring herpes zoster, zosterassociated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand. Int. J. Dermatol. 2011. p. 428–35.
25.
Laurent B, Vicaut E, Leplège A, Bloch K, Leutenegger E. Prevalence and impact on quality of life of post-herpetic neuralgia in French medical centers specialized in chronic pain management: The ZOCAD study. Med Mal Infect. 2014. p. 515–24.
26.
Oster G, Harding G, Dukes E, Edelsberg J, Cleary P. Pain, Medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005. p. 356–63.
27.
Deshpande M, Holden R, Gilron I. The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction? Anesth Analg. 2006. p. 1473–9.
28.
Vinik A, Emir B, Parsons B, Cheung R. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and postherpetic neuralgia. Pain Med. 2014. p. 661–70.
29.
Cao S, Song G, Zhang Y, Xie P, Tu Y, Li Y, et al. Abnormal local brain activity beyond the pain matrix in postherpetic neuralgia patients: a restingstate functional MRI Study. Pain Physician. 2017. p. E303-314.
30.
Freeman R, Wallace M, Sweeney M, Backonja M. Relationships among pain quality, pain impact, and overall improvement in patients with postherpetic neuralgia treated with gastroretentive gabapentin. Pain Med. 2015. p. 2000–11.
31.
Mick G, Hans G. Postherpetic neuralgia in Europe: the scale of the problem and outlook for the future. J. Clin. Gerontol Geriatr. 2013. p. 102–8.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
